James A - Search Results

1

Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).

Colombel JF, Ungaro RC, Sands BE, Siegel CA, Wolf DC, Valentine JF, Feagan BG, Neustifter B, Kadali H, Nazarey P, James A, Jairath V, Qasim Khan RM. Colombel JF, et al. Among authors: james a. Clin Gastroenterol Hepatol. 2023 Sep 22:S1542-3565(23)00746-2. doi: 10.1016/j.cgh.2023.09.010. Online ahead of print. Clin Gastroenterol Hepatol. 2023. PMID: 37743037 Free article.

2

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.

Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Feagan BG, et al. Among authors: james a. Clin Gastroenterol Hepatol. 2017 Feb;15(2):229-239.e5. doi: 10.1016/j.cgh.2016.08.044. Epub 2016 Sep 14. Clin Gastroenterol Hepatol. 2017. PMID: 27639327 Free article.

3

Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.

Feagan BG, Patel H, Colombel JF, Rubin DT, James A, Mody R, Lasch K. Feagan BG, et al. Among authors: james a. Aliment Pharmacol Ther. 2017 Jan;45(2):264-275. doi: 10.1111/apt.13852. Epub 2016 Nov 17. Aliment Pharmacol Ther. 2017. PMID: 27859410 Free PMC article. Clinical Trial.

4

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.

Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Sands BE, et al. Among authors: james a. Inflamm Bowel Dis. 2017 Jan;23(1):97-106. doi: 10.1097/MIB.0000000000000979. Inflamm Bowel Dis. 2017. PMID: 27930408 Clinical Trial.

5

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.

Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Feagan BG, et al. Among authors: james a. Inflamm Bowel Dis. 2019 May 4;25(6):1028-1035. doi: 10.1093/ibd/izy323. Inflamm Bowel Dis. 2019. PMID: 30365009 Free PMC article.

6

ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse.

Jairath V, Yarur A, Osterman MT, James A, Balma D, Mehrotra S, Yang L, Yajnik V, Qasim Khan RM. Jairath V, et al. Among authors: james a. Clin Gastroenterol Hepatol. 2024 May;22(5):1077-1086.e13. doi: 10.1016/j.cgh.2023.10.029. Epub 2023 Nov 10. Clin Gastroenterol Hepatol. 2024. PMID: 37951560 Free article. Clinical Trial.

7

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.

Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B, Lasch K. Yajnik V, et al. Among authors: james a. Adv Ther. 2017 Feb;34(2):542-559. doi: 10.1007/s12325-016-0467-6. Epub 2017 Jan 9. Adv Ther. 2017. PMID: 28070861 Free PMC article. Clinical Trial.

8

Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.

Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, Dellaripa PF, Aringer M, Pope J, Distler O, James A, Schlenker-Herceg R, Stowasser S, Quaresma M, Flaherty KR; INBUILD Trial Investigators. Matteson EL, et al. Among authors: james a. Arthritis Rheumatol. 2022 Jun;74(6):1039-1047. doi: 10.1002/art.42075. Epub 2022 May 2. Arthritis Rheumatol. 2022. PMID: 35199968 Free PMC article. Clinical Trial.

9

Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Considerations for paediatric patients.

Foley P, Mahar PD, Smith SD, Gupta M, Manuelpillai N, Orchard D, Wong LC, Su JC, James A, Fischer G, Marshman G, Rawlin M, Turner M, King E, Kennedy R, Baker C. Foley P, et al. Among authors: james a. Australas J Dermatol. 2024 May 13. doi: 10.1111/ajd.14303. Online ahead of print. Australas J Dermatol. 2024. PMID: 38741474

10

Examining prevalence and predictors of pulmonary hypertension in adults with idiopathic pulmonary fibrosis: a population-based analysis in the United States.

Desai R, Katukuri N, Kanagala SG, Ghadge N, James A, Tajdin B, Nalla A, Vutukuru SD, Kotharu DM, Kadiyala A, Vyas A, Prajjwal P, Ogbu I. Desai R, et al. Among authors: james a. J Med Life. 2024 Jan;17(1):35-40. doi: 10.25122/jml-2023-0324. J Med Life. 2024. PMID: 38737661 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,273 results

Search Page